



Is YUPELRI widely covered for my patients?

“YUP”

**Getting patients started on YUPELRI**

Please see full Important Safety Information on page 10  
and accompanying Full Prescribing Information.

# YUPELRI® (revefenacin) is covered through the Medicare Part B Benefit



Your patients' coverage and out-of-pocket costs for YUPELRI will depend on how Medicare administers their benefits\*

## Indication

YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

## Important Safety Information

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta<sub>2</sub>-agonist.

Please see full Important Safety Information on page 10 and accompanying Full Prescribing Information.

Out-of-pocket costs for YUPELRI are covered up to 100% for patients who have Medicare Part B<sup>†</sup>

80%

Medicare Part B covers 80% of the cost of YUPELRI

20%

Supplemental insurance plans may cover the patient's remaining 20% coinsurance

~80% of Medicare beneficiaries have supplemental insurance and pay as little as \$0 out of pocket for YUPELRI

Most nebulizers are covered by Medicare Part B as durable medical equipment (DME) for patient use at home<sup>1‡</sup>



\*Benefits are established by Centers for Medicare & Medicaid Services (CMS) local coverage determinations.


<sup>†</sup>This is not a guarantee of coverage. Site of care will determine coverage. Check with your patient's insurance provider for coverage rules and restrictions. In certain limited instances, YUPELRI may be covered through a patient's Medicare Part D pharmacy benefit.

<sup>‡</sup>DME suppliers may require additional documentation.

## Outpatient Medicare Coverage

Outpatient coverage applies to patients residing at home

### Original Medicare: Part B Benefit with or without supplemental insurance<sup>2</sup>



- Original Medicare pays 80% of the cost of YUPELRI® (revefenacin) inhalation solution. Patients are responsible for paying the remaining 20%
- Patients may pay as little as \$0 out of pocket per YUPELRI prescription with a supplemental insurance plan (Medigap, Employer-Sponsored, or Medicaid)
- Administered through the Centers for Medicare and Medicaid Services (CMS)

### Medicare Advantage: Part B Benefit<sup>3</sup> (also called Medicare Part C or Medicare replacement plan)




- An alternative to original Medicare administered through private insurance companies
- The plan delivers the Medicare benefit and therefore must adhere to the rules of Medicare
- Out-of-pocket costs vary depending on the patient's specific plan

Please see full Important Safety Information on page 10 and accompanying Full Prescribing Information.

## Inpatient Medicare Coverage


Inpatient coverage applies to patients in hospitals, skilled nursing facility care, hospice care, and home health care

### Medicare Part A or Medicare Advantage<sup>3</sup>



- YUPELRI may be covered by Medicare Part A or Medicare Advantage if it is administered in an inpatient, skilled nursing, nursing home (up to 90 days), hospice, or home health care setting


### Medicare Part D or Medicare Advantage<sup>3</sup> (Part D is an optional private prescription drug plan)



- Patients may be covered under Part D or Medicare Advantage if they are using YUPELRI in a skilled nursing facility or long-term care facility<sup>4</sup>
- Patients pay 100% of the cost of the medication until their deductible has been met, and no more than 25% of the cost of the drug thereafter<sup>5</sup>
- The majority of chronic-stay residents will be enrolled in Medicare Part D Low Income Subsidy (LIS) plans and will have no out-of-pocket costs

## Non-Medicare Coverage

### For patients with commercial or employer-sponsored (private) coverage



**~90% of patients with commercial or employer-sponsored (private) insurance pay \$0 out of pocket for YUPELRI<sup>6</sup>**

- Eligible patients with private or commercial insurance may use the YUPELRI Savings Card to help pay for their prescription\*
- The YUPELRI Savings Card may help lower out-of-pocket costs:
  - Up to a maximum of \$550 per 30-day prescription
  - Up to 12 times per calendar year
  - Up to a maximum of \$6,600 per calendar year

Learn more at [YUPELRIHCP.com](http://YUPELRIHCP.com)

\*Please see full terms and conditions at [YUPELRIHCP.com](http://YUPELRIHCP.com). This offer is not valid for patients covered through Medicare, Medicaid, or any other federal or state-funded healthcare program or where prohibited by law. Mylan Specialty L.P., a Viatrix Company, reserves the right to amend or end this program at any time without notice.

Please see full Important Safety Information on page 10 and accompanying Full Prescribing Information.

### For patients who need financial assistance

**YUPELRI can still be an option for patients who are uninsured or whose insurance doesn't cover YUPELRI**

- Through our Patient Assistance Program, patients in need may be able to receive their medication free of charge<sup>†</sup>
- For more information, please direct your eligible patients to contact us:



[customer.service@viatrix.com](mailto:customer.service@viatrix.com)



1-800-796-9526 (toll-free)

<sup>†</sup>Patients must meet financial and other program-specific criteria to be eligible for assistance.

### For new patients prescribed YUPELRI at hospital discharge

#### **YUPELRI 30-Day Trial Voucher Program<sup>‡</sup>**

- Free, 30-day trial supply for new-to-therapy patients
- Redeemable at retail, hospital, and specialty outpatient pharmacies

**VOUCHERS ARE ONLY AVAILABLE AT THE TIME OF HOSPITAL DISCHARGE**

<sup>‡</sup>Certain terms, conditions, and limitations apply. A valid prescription must be attached to the voucher. To continue a patient on therapy, a separate prescription will be needed. Vouchers cannot be redeemed at a DME supplier. Vouchers can be used by only one patient, one time. Ask your representative for a detailed list of terms, conditions, and limitations.





## Tips for expediting time to fulfillment

Missing information is the main reason for delayed approvals

- ★ Make sure ALL required information is included in your health plan or pharmacy request

**Required information** by Medicare or commercial health plans generally includes:


- ✓ Dosing instructions
- ✓ Quantity to be dispensed
- ✓ Number of refills
- ✓ J-Code: J7677
- ✓ Applicable ICD-10 COPD diagnosis code
- ✓ Relevant medical records (eg, prior therapies and reasons for discontinuation)

**Additional information** that may also be required by Medicare:

- ✓ A prescription for the jet nebulizer (if the patient does not already have one)
- ✓ Written documentation of need (detailing COPD evaluation and supporting the need for a nebulizer)

- ★ Send prescriptions to DME pharmacies, specialty pharmacies, or retail pharmacies based on your patient's type and/or preference

- ✓ Confirm the selected pharmacy receives the prescription and required information for both YUPELRI and a nebulizer, if needed
- ✓ Confirm the selected pharmacy is able and willing to process the patient's Medicare Part B benefit and supplemental insurance, if applicable
- ✓ Ensure the selected pharmacy files YUPELRI under Medicare Part B for appropriate patients and is able to process the patient's Medicare Part B supplemental insurance benefit, if applicable



## Follow up with your patients



Confirm that the patient has obtained their prescription(s)



Ask if they have begun taking YUPELRI



Determine whether they need help using their nebulizer properly or have any questions about their medication

**References:** 1. Nebulizers—Policy Article. Centers for Medicare & Medicaid Services website. Published October 1, 2015. Updated January 1, 2023. Accessed March 15, 2023. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52466> 2. Costs. Medicare.gov. Accessed July 11, 2023. <https://www.medicare.gov/basics/costs/medicare-costs> 3. Parts of Medicare. Medicare.gov. Accessed July 11, 2023. <https://www.medicare.gov/basics/get-started-with-medicare/medicare-basics/parts-of-medicare> 4. Health care & prescriptions in a nursing home. Medicare.gov. Accessed July 17, 2023. <https://www.medicare.gov/what-medicare-covers/what-part-a-covers/health-care-prescriptions-in-a-nursing-home> 5. Phases of Part D coverage. Medicareinteractive.org. Accessed July 17, 2023. <https://www.medicareinteractive.org/get-answers/medicare-prescription-drug-coverage-part-d/medicare-part-d-costs/phases-of-part-d-coverage> 6. Data on file, November 2020, Mylan Specialty L.P., a Viatris Company.

### Important Safety Information

As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.

YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.



Please see full Important Safety Information on page 10 and accompanying Full Prescribing Information.

## Important Safety Information

---

### Indication

---

YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

### Important Safety Information

---

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta<sub>2</sub>-agonist.

As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.

YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.

Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

YUPELRI is not recommended in patients with any degree of hepatic impairment.

**Please see accompanying Full Prescribing Information.**



**POCKET**



## Remember:

- ✓ YUPELRI is covered through the Medicare Part B benefit
- ✓ Patients with supplemental insurance may pay as little as \$0 for YUPELRI
- ✓ Missing information or documentation may result in the prescription being denied or delayed
- ✓ Not all pharmacies are able to process Medicare Part B coverage; other fulfillment options are available

## We're here to help!

Please contact me with any questions

BUSINESS CARD

**Please see full Important Safety Information on page 10 and accompanying Full Prescribing Information.**

YUPELRI and the Yupelri Logo are registered trademarks of Mylan Specialty L.P., a Viatris Company. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company. THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

© 2023 Viatris Inc. All Rights Reserved. REV-2023-0140 v2

